ClinicalTrials.gg
Not yet recruitingNCT06791824Updated Feb 18, 2025

Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia

A Phase 1/2 interventional study of CM313(SC) injection and CM313(SC) injection in Aplastic Anemia, sponsored by Keymed Biosciences Co.Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-18.

Sponsored by Keymed Biosciences Co.Ltd · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Anemia, Aplastic with a site in China — 39 open to participants now, 43 under way, 1 of them phase 3. Anemia, Aplastic · China.

Planned enrollment
11th of 74
125 · median 52
Started
2025
with 10 others
Phase 1/2
8 of 88
4 open now
Primary completion
2027-12
later than 28 of 42 live
Registered
66th of 88
by date

Among the 88 studies in Anemia, Aplastic with a site in China, this one is the 11th largest by planned enrollment of the 74 interventional ones that give a count, is one of 11 that started in 2025, is one of 8 in phase 1/2, reaches primary completion later than 28 of the 42 other live ones, and was the 66th registered.

Anemia, Aplastic

372 studies on the registry are indexed under Anemia, Aplastic; 99 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

39 of the 88 studies in Anemia, Aplastic with a site in China are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 59 Anemia, Aplastic studies recruiting now, 21 (36%) set no upper age limit and 30 (51%) stop at 75 or younger; 38 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Anemia, Aplastic with a site in China, or all of them as a file.
02

Study summary

This is a randomized, open-label, phase IB/II clinical study to evaluate the safety, tolerability and preliminary efficacy of CM313(SC) injection in patients with relapsed/refractory aplastic anemia

03

Conditions studied

  • Aplastic Anemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of idiopathic aplastic anemia.
  2. Patients must meet the requirements of aplastic anemia defined in the protocol.
  3. Male or female, age≥18 years.
  4. The (ECOG) physical status score ≤2.
  5. Willing and able to comply with the requirements for this study and written .

Exclusion criteria

Exclusion Criteria:

  1. The inherited bone marrow failure syndromes.
  2. Previously treated with the anti-CD38 monoclonal antibody.
  3. Have an allergy to humanized monoclonal antibody or any part of CM313.
  4. Pregnant or breastfeeding females, or females planning to become pregnant during the study.
  5. Any condition considered to be ineligible for the study by the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
125 participants (estimated)

Study arms

  • Experimental
    CM313(SC)(low dose group)

    Biological: CM313(SC) injection

  • Experimental
    CM313(SC)(medium dose group)

    Biological: CM313(SC) injection

  • Experimental
    CM313(SC)(high dose group)

    Biological: CM313(SC) injection

Interventions

  • Phase IB: CM313(SC) administered at low dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results.

  • Phase IB: CM313(SC) administered at medium dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results.

  • Phase IB: CM313(SC) administered at high dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results.

06

What researchers measure

Primary outcomes

  1. Adverse events (AE)

    Assess the safety and tolerability

    Time frame: Up to 52 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2025; primary completion for Dec 2027, 33 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2025
First posted
Jan 24, 2025
StartEst.
Mar 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Feb 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06791824
Responsible party
Sponsor
First posted
Jan 24, 2025
Start date
Mar 2025 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Feb 18, 2025

Study contacts

Qian Jia
Contact
qianjia@keymedbio.com
028-88610620
Jun Shi
principal investigator · Institute of Hematology & Blood Diseases Hospital, China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumrotatug

Start the discussion